ACUR · As filed with the SEC
Acura Pharmaceuticals income statement, by quarter
The statement as Acura Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS · USD, except per-share amounts
| USD, except per-share amounts | Q4 2021 3 months ended Dec 31, 2021 | Q3 2021 3 months ended Sep 30, 2021 | Q2 2021 3 months ended Jun 30, 2021 | Q1 2021 3 months ended Mar 31, 2021 |
|---|---|---|---|---|
| Revenues: | ||||
| Royalties | — | 67,000 | 3,000 | 32,000 |
| Collaboration from related party | — | 3,000 | 10,000 | 12,000 |
| License fees from related party | — | 200,000 | 600,000 | 600,000 |
| Product sales | — | 0 | 0 | — |
| Total revenues | — | 270,000 | 613,000 | 644,000 |
| Expenses: | ||||
| Research and development | — | 385,000 | 390,000 | 405,000 |
| General and administrative | — | 416,000 | 523,000 | 385,000 |
| Total expenses | — | 801,000 | 913,000 | 790,000 |
| Operating loss | — | (531,000) | (300,000) | (146,000) |
| Interest expense - related party (Note 9) | — | — | (87,000) | — |
| Gain on forgiveness of a loan under CARES Act | — | 269,000 | — | — |
| Interest expense to related party | — | 0 | — | (113,000) |
| Loss before provision for income taxes | — | (262,000) | (387,000) | (259,000) |
| Provision for income taxes | — | 0 | 0 | 0 |
| Net loss | — | (262,000) | (387,000) | (259,000) |
| Net income (loss) per share: | ||||
| Basic | — | 0.00 | (0.01) | (0.01) |
| Diluted | — | 0.00 | (0.01) | (0.01) |
| Weighted average number of shares outstanding: | ||||
| Basic | — | 75,561,000 | 42,889,000 | 32,464 |
| Diluted | — | 75,561,000 | 42,889,000 | 32,464 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.